Vapendavir - Vaxart

Drug Profile

Vapendavir - Vaxart

Alternative Names: BTA-798

Latest Information Update: 16 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biota Holdings
  • Developer Aviragen Therapeutics; Biota Pharmaceuticals; Vaxart
  • Class Antivirals; Benzoxazoles; Small molecules
  • Mechanism of Action Capsid protein inhibitors; Rhinovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rhinovirus infections

Most Recent Events

  • 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rhinovirus-infections(In volunteers) in USA (PO, Tablet)
  • 04 Apr 2017 Aviragen Therapeutics withdraws a phase II trial, prior to enrolment, in Rhinovirus infections (in haematopoietic stem cell transplant patients, In adolescents, In adults, In the elderly) based on analysis of SPIRITUS trial data
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top